Trial Profile
A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Acronyms GO-VIVA
- Sponsors Janssen Research & Development
- 27 Feb 2024 Planned End Date changed from 6 Feb 2029 to 8 Feb 2029.
- 15 Nov 2023 Results assessing pharmacokinetics, immunogenicity, efficacy, and safety of Golimumab in GO-VIVA participants who continued into the long-term extension (LTE) through W252, were presented at the ACR Convergence 2023.
- 10 Oct 2023 Planned End Date changed from 6 Feb 2032 to 6 Feb 2029.